Recursion Pharmaceuticals has integrated its drug discovery platform with Exscientia’s AI-driven chemistry, streamlining its research and development efforts. During a recent discussion led by Chief Financial Officer Ben Taylor, the company outlined its strategy for enhancing drug discovery through the combined capabilities of phenomics and a new ClinTech platform utilizing real-world data. The firm has consolidated its research focus to five internal clinical programs and approximately 15 discovery initiatives while securing over $500 million from partners, including Sanofi and Roche, with average program milestones around $300 million.
Recursion’s recent advancements were highlighted by a promising proof-of-concept study in an orphan indication known as FAP, which demonstrated nearly 50% responses after three months with durable effects even after discontinuation of treatment. The company is currently discussing a pivotal trial pathway with the FDA and anticipates multiple clinical readouts and the commencement of a pivotal trial in the first half of next year.
Ending the year with $754 million in cash provides a runway into early 2028. Recursion has achieved significant cost reductions, cutting spending by over $200 million and claiming efficiency gains such as reducing chemical development costs by around 90% and shortening the timeline from idea to compound to 17 months from the industry standard of 42 months.
Speaking during the fireside chat hosted by KeyBank healthcare tech equity analyst Scott Schoenhaus, Taylor discussed the combined company’s strategy to address multiple points of failure in drug development. He emphasized that Exscientia’s expertise in AI for chemistry, particularly in multi-parameter optimization—considering factors like potency, selectivity, absorption, metabolism, and toxicity—enhances the overall drug discovery process.
On the legacy side of Recursion, Taylor underscored the importance of exploring new biological ideas, noting that only about 3% of the genome has an approved drug associated with it, and even with drugs in development, this figure barely exceeds 10%. He characterized the remaining 90% as largely unexplored territory, indicating ample opportunity for innovation.
Recursion has developed a “phenomic system” that employs techniques such as transcriptomics and real patient data to identify potential targets and hypotheses. The newly established ClinTech business further integrates real-world data to optimize patient selection and clinical trial design, reporting improvements in enrollment rates of between 30% and 60%.
The merger has expanded Recursion’s R&D capabilities significantly, with Taylor noting that the company is now overseeing about 10 clinical agents along with additional preclinical programs. He described a thorough review process aimed at evaluating the scientific rationale, clinical plans, and commercial potential for each program. Consequently, Recursion has streamlined its focus to five internal clinical projects, supplemented by around 15 discovery programs, both internal and in partnership.
Partnerships are central to Recursion’s business model, with Sanofi and Roche being primary collaborators. Taylor reported that Recursion has achieved initial milestones on five programs with Sanofi, which are particularly promising due to their potential to address challenging industry issues such as druggability and first-in-class biology. He highlighted that the development-candidate milestone is especially appealing as it allows for profit that “drops to the bottom line,” effectively concluding operational obligations on the program.
Regarding the Roche collaboration, initiated in the neuroscience domain, Taylor mentioned that it has led to innovative maps of neurological cells. Roche provided an upfront payment of $150 million and Recursion has already secured $60 million in milestone payments tied to the success of these maps. The goal is to evolve this partnership into programs that align with the model established with Sanofi.
Discussing patient enrollment strategies, Taylor stated that Recursion leverages real-world data from over six providers, which has resulted in significant enhancements to trial design and selection, ultimately improving enrollment rates and potentially reducing overall drug development costs. He noted that clinical trials represent a significant portion of drug development expenses, accounting for 70 cents out of every dollar, which underscores the need for improved patient targeting.
Looking ahead, Recursion aims to validate its technology incrementally rather than scaling prematurely. The company is currently managing over 20 internal programs and is focused on a rigorous portfolio management strategy that prioritizes the continuation of successful initiatives while ceasing those that do not yield results. Taylor asserted that even if multiple clinical programs succeed, not all are guaranteed to advance independently, contingent on operational capabilities.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) continues to innovate at the intersection of advanced automation, artificial intelligence, and high-throughput biology aimed at the discovery and development of novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with extensive cellular imaging and chemical biology to expedite the drug discovery process and broaden the range of targetable conditions.
See also
DeepSeek vs ChatGPT: 2026 Performance, Cost, and Features Compared for AI Professionals
Germany”s National Team Prepares for World Cup Qualifiers with Disco Atmosphere
95% of AI Projects Fail in Companies According to MIT
AI in Food & Beverages Market to Surge from $11.08B to $263.80B by 2032
Satya Nadella Supports OpenAI’s $100B Revenue Goal, Highlights AI Funding Needs
